Exclusion of pregnant women from industry-sponsored clinical trials

Obstetrics and Gynecology

Volumn 122, Issue 5, 2013, Pages 1077-1081

  Shields, Kristine E ^a   Lyerly, Anne Drapkin ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG INDUSTRY; FUTUROLOGY; HEALTH; HUMAN; INDUSTRY SPONSORED CLINICAL TRIAL; INTERVENTION STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

CLINICAL TRIALS, PHASE IV AS TOPIC; DRUG INDUSTRY; FEMALE; HUMANS; PATIENT SELECTION; PREGNANCY; PREGNANT WOMEN; UNITED STATES;

EID: 84887166744     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182a9ca67     Document Type: Review

References (18)

1. Mastroianni AC, Faden R, Federman D, editors. Women and health research: Ethical and legal issues of including women in clinical studies. Institute of Medicine. Washington (DC): National Academy Press; 1994.
2. Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Available at: http://www.cioms.ch/images/stories/CIOMS/guidelines/ guidelines-nov-2002-blurb.htm. Retrieved April 17, 2011.
3. Research involving women. ACOG Committee Opinion No. 377. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007; 110: 731-6.
4. Lagakos SW, Gable A, editors. Design considerations: Methodological challenges in biomedical HIV Prevention Trials. Institute of Medicine. Washington, DC: National Academies Press; 2008: 104-8.
5. FDA guidance document to-do list. "The pink sheet". 2011. Available at: http://www.elsevierbi.com/publications/the-pinksheet? issue5Jan-03-2011. Retrieved March 22, 2011.
6. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158-66.
7. Phase 4 commitment category-Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DevelopmentApproval- Process/ FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ ucm071716.htm. Retrieved May 5, 2013.
8. Physicians' Desk Reference online version, PDR.net. Available at: www.PDR.net. Retrieved October 2011 through January 2012.
9. U.S. Code of Federal Regulations, title 45, part 46, subpart B 2009. U.S. Government Printing Office via GPO access [Cite: 45CFR46]. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#subpartb. Retrieved May 2, 2011.
10. Lyerly AD, Namey EE, Gray B, Swamy G, Faden RR. Women's views about participating in research while pregnant. IRB 2012; 34: 1-8.
11. Rodger MA, Makropoulos D, Walker M, Keely E, Karovitch A, Wells PS. Participation of pregnant women in clinical trials: will they participate and why? Am J Perinatol 2003;20:69-6.
12. Lyerly AD, Little M, Faden RR. Pregnancy and clinical research. Hastings Cent Rep 2008;38:53.
13. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada- Vera B. Deaths: final data for 2006. National Vital Statistics Report 2009. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57-14.pdf. Retrieved April 22, 2012.
14. Andrade SE, Gurwitz JH, Davis RL. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-7.
15. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.el-8.
16. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural obstetric population. Am J Obstet Gynecol 2003;188:1039-45.
17. Lo WY, Friedman JM. Evolving knowledge of the teratogenicity of medication in human pregnancy. Obstet Gynecol 2002; 100:465-73.
18. Adam MP, Polifka JE, Friedman JM. "Teratogenicity of recently introduced medications in human pregnancy". Am J Med Genet C Semin Med Genet 2011;176:175-82.